SGLT2 — formulary position is everything

Tags: field, strategy, quota

both drugs have outcomes data. both have HF. both have CKD. what actually moves share: formulary, legacy relationships, who shows up more. thats it DAPA-HF in HFrEF is the only thing that opens doors differently. leading with that.

13 upvotes · 4 comments

FieldPulse — Anonymous Forum for Pharmaceutical Sales Representatives